“A GREAT OFFICE FOR LICENSING“ IAM MAGAZINE 2016
Horn & Co. represented Spacemesh in a Series A $15M financing round led by Polychain Ventures, with participation from the world’s leading blockchain oriented investment funds. The Horn & Co. team was led by Yuval Horn, Ohad Mamann and Maya Weiss Donin. Tomer Afek, Aviv Eyal and Ifat Linur – congratulations on this impressive milestone!
Proud to lead the list of top Israeli firms specializing in Hi-tech with an equal number of female and male partners, as described in this interesting article by @themarker.
Yuval Horn and Keren Kanir of Horn & Co. represented Anima Biotech in an exclusive collaboration agreement with Eli Lilly, with a total deal value exceeding $1 billion.
Proud to be ranked, again, by IAM Magazine (Intellectual Asset Management) as one of top 4 “highly recommended” Israeli firms in intellectual property transactions: “Horn & Co’s small size belies the reputation it enjoys with regard to the commercialisation of intellectual property.
Congratulations to our client, Zebra Medical for closing an impressive $30M financing round led by aMoon Ventures, with participation from Aurum, Johnson & Johnson Innovation and additional new and current investors.
Yuval Horn chosen as “Thought Leader” of Life Sciences Transactions by Who’s Who Legal: Life Sciences 2018.
Horn & Co. has been recognized again by Legal 500 as a “Tier 1” firm in Israel in the field of Healthcare and Life Sciences.
Yuval Horn and Ohad Mamann of Horn & Co. represented Pontifax, who led a €16 million Series A round and restructuring in ABAC Therapeutics, Inc.